Frontiers in Oncology (Mar 2022)

Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor

  • Xiao-chen Song,
  • Yong-xue Wang,
  • Mei Yu,
  • Dong-yan Cao,
  • Jia-xin Yang

DOI
https://doi.org/10.3389/fonc.2022.789228
Journal volume & issue
Vol. 12

Abstract

Read online

Malignant transformations, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), are rare tumors. The management of recurrent disease is still a challenge, and the gene mutations involved remain unclear. We herein report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) >10%. This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy.

Keywords